24164733|t|Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
24164733|a|BACKGROUND: Behavioral and psychological symptoms of dementia (BPSD) occur in up to 80% of Alzheimer's disease (AD) patients and represent one of the most common reasons for early institutionalization and increase in management costs. OBJECTIVES: This study evaluated the effects of four drugs (memantine, donepezil, rivastigmine, galantamine) in BPSD in AD patients. METHODS: This was a prospective, longitudinal, randomized, open-label, 4-arm, parallel-group, 12-month clinical trial carried out in 177 AD patients. The severity of BPSD was evaluated at baseline and after treatment with memantine (n = 48), donepezil (n = 42), rivastigmine (n = 46), and galantamine (n = 41), by using the Neuropsychiatric Inventory (NPI) and the Behavioural Pathology in Alzheimer's Disease (BEHAVE-AD) scales. RESULTS: The NPI and BEHAVE-AD total scores improved from baseline to month 12 in all groups. The improvements in both scales were statistically significant in the memantine, donepezil, and rivastigmine groups, but not in the galantamine group. Responder analyses showed that treatment with memantine and rivastigmine resulted in more patients improving on NPI and BEHAVE-AD score, respectively. Agitation/aggression was the NPI item with the highest improvements (significantly versus baseline in the memantine and in the rivastigmine groups), while aggression and anxiety/phobias were the mostly improved BEHAVE-AD items (significantly in the rivastigmine group for both and in the rivastigmine group only for anxiety/phobias). All treatments were well tolerated: most of adverse events reported were transient and of mild-to-moderate intensity. CONCLUSIONS: This study suggests that specific drugs for AD, especially memantine and rivastigmine, may be effective in the improvement of BPSD in patients with mild to moderate AD, without major side effects.
24164733	55	92	behavioral and psychological symptoms	Disease	MESH:D000067073
24164733	96	104	patients	Species	9606
24164733	110	129	Alzheimer's disease	Disease	MESH:D000544
24164733	185	222	Behavioral and psychological symptoms	Disease	MESH:D000067073
24164733	226	234	dementia	Disease	MESH:D003704
24164733	236	240	BPSD	Disease	MESH:D000067073
24164733	264	283	Alzheimer's disease	Disease	MESH:D000544
24164733	285	287	AD	Disease	MESH:D000544
24164733	289	297	patients	Species	9606
24164733	468	477	memantine	Chemical	MESH:D008559
24164733	479	488	donepezil	Chemical	MESH:D000077265
24164733	490	502	rivastigmine	Chemical	MESH:D000068836
24164733	504	515	galantamine	Chemical	MESH:D005702
24164733	520	524	BPSD	Disease	MESH:D000067073
24164733	528	530	AD	Disease	MESH:D000544
24164733	531	539	patients	Species	9606
24164733	678	680	AD	Disease	MESH:D000544
24164733	681	689	patients	Species	9606
24164733	707	711	BPSD	Disease	MESH:D000067073
24164733	763	772	memantine	Chemical	MESH:D008559
24164733	783	792	donepezil	Chemical	MESH:D000077265
24164733	803	815	rivastigmine	Chemical	MESH:D000068836
24164733	830	841	galantamine	Chemical	MESH:D005702
24164733	918	930	Pathology in	Disease	MESH:D005598
24164733	931	950	Alzheimer's Disease	Disease	MESH:D000544
24164733	959	961	AD	Disease	MESH:D000544
24164733	999	1001	AD	Disease	MESH:D000544
24164733	1135	1144	memantine	Chemical	MESH:D008559
24164733	1146	1155	donepezil	Chemical	MESH:D000077265
24164733	1161	1173	rivastigmine	Chemical	MESH:D000068836
24164733	1197	1208	galantamine	Chemical	MESH:D005702
24164733	1262	1271	memantine	Chemical	MESH:D008559
24164733	1276	1288	rivastigmine	Chemical	MESH:D000068836
24164733	1306	1314	patients	Species	9606
24164733	1343	1345	AD	Disease	MESH:D000544
24164733	1367	1376	Agitation	Disease	MESH:D011595
24164733	1377	1387	aggression	Disease	MESH:D010554
24164733	1473	1482	memantine	Chemical	MESH:D008559
24164733	1494	1506	rivastigmine	Chemical	MESH:D000068836
24164733	1522	1532	aggression	Disease	MESH:D010554
24164733	1537	1552	anxiety/phobias	Disease	MESH:D001007
24164733	1585	1587	AD	Disease	MESH:D000544
24164733	1616	1628	rivastigmine	Chemical	MESH:D000068836
24164733	1655	1667	rivastigmine	Chemical	MESH:D000068836
24164733	1683	1698	anxiety/phobias	Disease	MESH:D001007
24164733	1876	1878	AD	Disease	MESH:D000544
24164733	1891	1900	memantine	Chemical	MESH:D008559
24164733	1905	1917	rivastigmine	Chemical	MESH:D000068836
24164733	1958	1962	BPSD	Disease	MESH:D000067073
24164733	1966	1974	patients	Species	9606
24164733	1997	1999	AD	Disease	MESH:D000544
24164733	Negative_Correlation	MESH:D000077265	MESH:D000067073
24164733	Comparison	MESH:D000068836	MESH:D008559
24164733	Negative_Correlation	MESH:D000077265	MESH:D000544
24164733	Positive_Correlation	MESH:D008559	MESH:D010554
24164733	Negative_Correlation	MESH:D000068836	MESH:D011595
24164733	Comparison	MESH:D000068836	MESH:D000077265
24164733	Negative_Correlation	MESH:D000068836	MESH:D001007
24164733	Negative_Correlation	MESH:D008559	MESH:D000544
24164733	Negative_Correlation	MESH:D000068836	MESH:D000544
24164733	Negative_Correlation	MESH:D005702	MESH:D000544
24164733	Negative_Correlation	MESH:D005702	MESH:D000067073
24164733	Negative_Correlation	MESH:D000068836	MESH:D000067073
24164733	Negative_Correlation	MESH:D008559	MESH:D011595
24164733	Comparison	MESH:D000068836	MESH:D005702
24164733	Negative_Correlation	MESH:D008559	MESH:D000067073
24164733	Positive_Correlation	MESH:D000068836	MESH:D010554
24164733	Comparison	MESH:D000077265	MESH:D008559

